Evidence map›Paper›PMID 26354994›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2015

Role of µ, κ, and δ opioid receptors in tibial inhibition of bladder overactivity in cats.

Zhaocun Zhang, Richard C Slater, Matthew C Ferroni, Brian T Kadow, Timothy D Lyon, Bing Shen, Zhiying Xiao, Jicheng Wang, Audry Kang, James R Roppolo and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Prolonged nonobstructive urinary retention induced by tibial nerve stimulation in cats.American journal of physiology. Regulatory, integrative and comparative physiology · 2020
    Article
  9. Article
  10. Glutamatergic Mechanisms Involved in Bladder Overactivity and Pudendal Neuromodulation in Cats.The Journal of pharmacology and experimental therapeutics · 2017
    Article
  11. Article
  12. Sex difference in the contribution of GABAAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2017
    Article
  13. Neurotransmitter Mechanisms Underlying Sacral Neuromodulation of Bladder Overactivity in Cats.Neuromodulation : journal of the International Neuromodulation Society · 2017
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Zhaocun ZhangDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Richard C SlaterDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Matthew C FerroniDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Brian T KadowDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Timothy D LyonDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Bing ShenDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Zhiying XiaoDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Jicheng WangDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Audry KangDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
James R RoppoloDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
William C de GroatDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Changfeng TaiDepartment of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.) cftai@pitt.edu.
Qilu Hospital of Shandong University · CNSecond Hospital of Shandong University · CNUniversity of Pittsburgh · USShandong University · CN

Funding

Bladder Nociception: function/central projection of Sympathetic Afferent PathwayR01DK091253 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEGROAT, WILLIAM C · 2011 to 2015
$1.7M
Neurotransmitter Receptors Involved in Neuromodulation of Bladder OveractivityR01DK102427 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAI, CHANGFENG · 2014 to 2017
$924k
Central Sites of Action for Bladder NeuromodulationR01DK094905 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAI, CHANGFENG · 2013 to 2016
$922k
New Strategies to Treat Overactive BladderR01DK090006 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAI, CHANGFENG · 2010 to 2013
$781k
NIDDK NIH HHS DK-090006NIDDK NIH HHS DK-091253NIDDK NIH HHS DK-094905NIDDK NIH HHS DK-102427NIDDK NIH HHS R01 DK090006NIDDK NIH HHS R01 DK091253NIDDK NIH HHS R01 DK094905NIDDK NIH HHS R01 DK102427
6 · The paper itself

Abstract

In α-chloralose anesthetized cats, we examined the role of opioid receptor (OR) subtypes (µ, κ, and δ) in tibial nerve stimulation (TNS)-induced inhibition of bladder overactivity elicited by intravesical infusion of 0.25% acetic acid (AA). The sensitivity of TNS inhibition to cumulative i.v. doses of selective OR antagonists (cyprodime for µ, nor-binaltorphimine for κ, or naltrindole for δ ORs) was tested. Naloxone (1 mg/kg, i.v., an antagonist for µ, κ, and δ ORs) was administered at the end of each experiment. AA caused bladder overactivity and significantly (P < 0.01) reduced bladder capacity to 21.1% ± 2.6% of the saline control. TNS at 2 or 4 times threshold (T) intensity for inducing toe movement significantly (P < 0.01) restored bladder capacity to 52.9% ± 3.6% or 57.4% ± 4.6% of control, respectively. Cyprodime (0.3-1.0 mg/kg) completely removed TNS inhibition without changing AA control capacity. Nor-binaltorphimine (3-10 mg/kg) also completely reversed TNS inhibition and significantly (P < 0.05) increased AA control capacity. Naltrindole (1-10 mg/kg) reduced (P < 0.05) TNS inhibition but significantly (P < 0.05) increased AA control capacity. Naloxone (1 mg/kg) had no effect in cyprodime pretreated cats, but it reversed the nor-binaltorphimine-induced increase in bladder capacity and eliminated the TNS inhibition remaining in naltrindole pretreated cats. These results indicate a major role of µ and κ ORs in TNS inhibition, whereas δ ORs play a minor role. Meanwhile, κ and δ ORs also have an excitatory role in irritation-induced bladder overactivity.

Indexed as

Tibial NerveTranscutaneous Electric Nerve StimulationAcetic AcidAnimalsCatsFemaleMaleMorphinansNaloxoneNaltrexoneReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, muUrinary Bladder, OveractiveAcetic AcidcyprodimeMorphinansNaloxoneNaltrexonenaltrindolenorbinaltorphimineReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, mu

Identifiers

PMID26354994
PMCPMC4613954
OpenAlexW1547474945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.